Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-2 (α2) adrenergic receptor is a G protein-coupled receptor (GPCR) that primarily couples to the Gi class of heterotrimeric G-proteins. It plays a key role in modulating neurotransmitter release, vascular tone, and several central nervous system functions by responding to endogenous catecholamines such as norepinephrine and epinephrine. There are three main subtypes: α2A, α2B, and α2C. Activation inhibits adenylyl cyclase, reducing cAMP levels and resulting in decreased neurotransmitter release, sedation, analgesia, hypotension, and bradycardia. Agonists targeting these receptors have diverse clinical uses, including hypertension management, sedation, ADHD treatment, and muscle spasticity reduction.
Agonists bind to the α2-AR, activating Gi/o proteins. This inhibits adenylyl cyclase, reducing cAMP levels and leading to decreased neurotransmitter release, sedation, analgesia, and altered vascular tone.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-2 Adrenergic Receptor (α2-AR).